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Abstract 
Rapid and specific detection of extended‑spectrum β‑lactamase‑producing (ESBL) bacteria is crucial both for timely 
antibiotic therapy when treating infected patients as well as for appropriate infection control measures aimed at 
curbing the spread of ESBL‑producing isolates. Whereas a variety of phenotypic methods are currently available for 
ESBL detection, they remain time consuming and sometimes difficult to interpret while being also affected by a lack 
of sensitivity and specificity. Considering the longer turnaround time (TAT) of susceptibility testing and culture results, 
DNA‑based ESBL identification would be a valuable surrogate for phenotypic‑based methods. Putative ESBL‑positive 
Enterobacteriaceae isolates (n = 330) from clinical specimen were prospectively collected in Bulgaria, Romania and 
Democratic Republic of Congo and tested in this study. All isolates were assessed for ESBL‑production by the E‑test 
method and those giving undetermined ESBL status were re‑tested using the combination disk test. A genotypic 
assay successively combining qPCR detection of blaCTX‑M, blaTEM and blaSHV genes with a multiplex pyrosequenc‑
ing of blaTEM and blaSHV genes was developed in order to detect the most common ESBL‑associated TEM and SHV 
single nucleotides polymorphisms, irrespective of their plasmid and/or chromosomal location. This assay was applied 
on all Enterobacteriaceae isolates (n = 330). Phenotypic and genotypic results matched in 324/330 (98.2%). Accord‑
ingly, real‑time PCR combined with multiplex pyrosequencing appears to be a reliable and easy‑to‑perform assay with 
high‑throughput identification and fast TAT (~5 h).
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Introduction
Beta-lactams are antimicrobial drugs sharing a β-lactam 
ring structure (Kong et  al. 2009). They are among the 
most commonly prescribed drugs worldwide, espe-
cially for treatment of infections caused by Gram-neg-
ative bacteria (GNB) (Poole 2004; Paterson 2006; Pitout 
et al. 1997). A major shortcoming of this massive use of 
β-lactams antibiotics is the sharp and steady increase of 
antimicrobial resistance as evidenced worldwide over 
the past decades (Pitout and Laupland 2008; Gibold et al. 
2014). The main resistance mechanism is the synthesis 
of β-lactamases which retain the ability of hydrolyzing 
the β-lactam ring of a wide range of β-lactam antibiot-
ics, including penicillins, cephalosporins and carbap-
enems (Drawz and Bonomo 2010; Bush 2010). These 
hydrolyzing enzymes are encoded by genes located 
either on bacterial chromosomes or on extra-chromo-
somal transferable mobile elements (Poole 2004). So 
far, more than 1,300 β-lactamases have been described 
(Bush 2013) (http://www.lahey.org/studies/) and divided 
in four molecular classes (A–D) depending on their 
amino acids sequence (Jacoby and Munoz-Price 2005). 
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Class A β-lactamases, which is mainly found in GNB, is 
the most prevalent worldwide. Among GNB, extended 
spectrum β-lactamases (ESBLs) are the most common 
as illustrated by ESBL-producing Enterobacteriaceae 
which have emerged as an important cause of a wide 
spectrum of infections (Giamarellou 2005; Owens and 
Lautenbach 2008). ESBLs confer resistance to penicillins, 
cephalosporins (first-, second- and third-generation), and 
aztreonam while retaining susceptibility to clavulanate 
(Paterson and Bonomo 2005). Many ESBLs are derived 
from β-lactamase variants arising from amino acids 
substitutions that enable enzymes to hydrolyze vari-
ous β-lactam antibiotics (Bradford 2001; Haanperä et al. 
2008). Among class A ESBL families, the two main repre-
sentatives are TEM and SHV in which amino acids sub-
stitutions occur in blaTEM and blaSHV genes (Pfaller 
and Segreti 2006). In fact, some isolates may carry con-
comitantly a chromosomal β-lactamase (most commonly 
SHV-1 or TEM-1) and the plasmid variants derived 
from the chromosomal blaSHV or blaTEM gene. This 
chromosomal β-lactamase may interfere with molecular 
detection of the ESBL gene usually residing in plasmids 
(Haanperä et al. 2008; Jones et al. 2009).
Another major ESBL family is CTX-M which derives 
from Klyuvera spp (Rossolini et al. 2008). The successful 
spread of ESBLs in a wide range of Enterobacteriaceae 
can be attributed to the fact that the genes coding for 
ESBLs are often located on self-transmissible or mobiliz-
able broad-host-range plasmids (Livermore et  al. 2007; 
D’Andrea et al. 2013).
Extended-spectrum β-lactamase detection is crucial 
both for infection control measures as well as for select-
ing appropriate antimicrobial therapy, as failure to rap-
idly and unambiguously identify ESBL-producing isolates 
may delay the initiation of appropriate infection control 
measures and further contribute to their spread in hospi-
tal and community settings (Bradford 2001).
In the majority of healthcare facilities, the routine 
detection of ESBL production by Enterobacteriaceae is 
actually carried out by phenotypic methods (Pitout and 
Laupland 2008). These tests are based on the principle 
that most ESBLs hydrolyze third-generation cephalo-
sporins and are inhibited by clavulanic acid (Robin et al. 
2008; Jarlier et al. 1988; Cormican et al. 1996; Carter et al. 
2000). Most guidelines recommend to first screen iso-
lates for decreased susceptibility to extended-spectrum 
cephalosporins in primary susceptibility testing, and then 
to carry out a confirmatory test to verify ESBL produc-
tion (Gazin et al. 2012; Garrec et al. 2011; Rupp and Fey 
2003). However, and despite the variety of phenotypic 
methods available and the existence of various guidelines 
available for the phenotypic detection of ESBL-producing 
bacteria, this remains a contentious issue, and proficiency 
testing shows that compliance varies widely across differ-
ent parts of the world (Pitout and Laupland 2008). For 
instance, it has been reported that laboratories fail to 
interpret correctly the inhibition ellipse in 30% of cases. 
Indeed, the enzymes may vary in their substrate affinities 
and in their catalytic efficiencies, and also differ in their 
penetration rates into bacterial cells (Drieux et al. 2008). 
Furthermore, the emergence of AmpC β-lactamases 
complicates the detection of ESBL-production. Indeed, 
AmpC β-lactames display high resistance rate to cepha-
losporins without retaining any susceptibility to clavula-
nate (Polsfuss et al. 2011). This observation is important, 
considering the recent emergence of plasmidic AmpC 
β-lactamases species like Escherichia coli and Klebsiella 
spp (Jacoby 2009).
In that respect, DNA-based detection of ESBL-pro-
duction appears as a valuable alternative to the pheno-
typic-based methods. It is indeed independent of gene 
expression and relatively rapid as compared with suscep-
tibility testing and culture results. In addition, this type of 
assay could help unravel issues related to ESBL-produc-
ing isolates, among which false-negative or indetermi-
nate results.
Several molecular tests aiming to detect and/or char-
acterize TEM, SHV and CTX-M have previously been 
described (Naas et al. 2007; Haanperä et al. 2008; Oxace-
lay et  al. 2009; Jones et  al. 2009; Leinberger et  al. 2010; 
Cohen Stuart et al. 2010; Al-Agamy et al. 2014). However, 
despite these encouraging achievements, technological 
limitations still hamper their implementation in routine 
microbiology practice, mainly due to the fact that they 
are still cumbersome and time-consuming (Drieux et al. 
2008; Wintermans et al. 2013). Consequently, there is still 
a need for molecular high-throughput techniques detect-
ing rapidly and reliably ESBL-producing isolates.
The aim of the current study was to develop and test 
a multiplex pyrosequencing assay for quick and unam-
biguous detection of ESBL-producing Enterobacteriaceae 
isolates. In this work, real-time PCR amplification of 
blaCTX-M, blaSHV and blaTEM genes was completed 
by multiplex pyrosequencing characterization of blaTEM 
and blaSHV in order to detect ESBL associated vari-




Various clinical specimens [including blood culture, 
peritoneal, pleural and pericardial fluids, urine, pus and 
sputum; n  =  330)] were collected between 2008 and 
2014 from patients from Bucharest Clinical Emergency 
Hospital (Romania; n  =  177), from the Intensive Care 
Unit (ICU) at the Military Medical Academy of Sofia 
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(Bulgaria; n =  144) and from various hospital wards of 
the Bukavu Provincial General Hospital (South Kivu 
province, Democratic Republic of Congo; n =  9). After 
initial culture, presumptive Enterobacteriaceae isolates 
from DR Congo were identified using standard micro-
biological methods whereas isolates from Bulgaria and 
Romania were identified using the Vitek-2 automated 
instrument ID system (BioMérieux, Marcy l’Etoile, 
France). Four commercial strains were used as negative 
and positive controls: ATCC-35218 (non-ESBL produc-
ing E. coli), ATCC-700603 (SHV-18 type β-lactamase 
producing K. pneumoniae), DSM-22314 (TEM-46 ESBL 
producing E. coli), and DSM-22313 (TEM-50 ESBL pro-
ducing E. coli), (see Table 1).
Susceptibility testing
In Romania and Bulgaria, ESBL-production assay was 
performed using Vitek-2 cards whereas in DRC, it was 
carried out by the double-disk synergy test on Muel-
ler–Hinton II® Agar (Oxoid Ltd, Cambridge, UK) using 
disks soaked with ceftazidime or cefotaxime (30 µg each) 
placed at a distance of 20  mm apart from a disk con-
taining amoxicillin plus clavulanic acid (10 µg). A clear-
cut enhancement of the inhibition in front of either 
ceftazidime and cefotaxime disks towards the clavulanic 
acid-containing disk (also called “champagne-cork” or 
“keyhole”) was interpreted as positive for ESBL produc-
tion (Drieux et al. 2008).
E-test® strips (BioMérieux, Marcy l’Etoile, France) were 
used for confirmation of ESBL-production. Minimum 
inhibitory concentrations (MIC) of ceftazidime and cefo-
taxime with and without clavulanic acid were determined 
after 16–18  h incubation on ISO Sensitest® Agar plates 
inoculated with suspension of isolates at a fixed density 
(0.5–0.6 McFarland standard). The test was performed 
and interpreted according to the manufacturer’s instruc-
tions. Escherichia coli ATCC 35218 and Klebsiella pneu-
moniae ATCC 700603 strains were used as ESBL negative 
and positive controls, respectively.
Each isolate generating a non-determinate (ND) result 
with this gradient test was retested using the combina-
tion disk test (CDT) as described by Carter (Carter et al. 
2000). In brief, disks containing 30 µg of cefotaxime, cef-
tazidime or cefepime and disks containing a combination 
of each of these drugs with 10  µg clavulanic acid (Bio-
Rad, Nazareth Eke, Belgium) were placed independently 
on a 0.5 McFarland opacity lawn culture of the tested 
isolate on a ISO Sensitest® Agar plate and incubated for 
18–24 h at 37°C. Isolates were considered ESBL-produc-
ing if the inhibition zone measured around one of the 
combination disks was at least 5  mm larger that of the 
corresponding cephalosporin disk.
DNA extraction and DNA‑based identification of isolates
For each isolate, a single colony was selected after over-
night growth on ISO-Sensitest® agar plate and cultured 
in fresh ISO-Sensitest® broth (Oxoid Ltd, Cambridge, 
UK) for 6  h. The broth was centrifuged and DNA sub-
sequently extracted from the pelleted cells using a DNA 
tissue kit with on the BioRobot EZ1 (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions.
Purified DNA was quantified using NanoDrop 
ND1000® spectrophotometer (Nanodrop Technologies, 
Inc. Wilmington, DE, US) and stored at −20°C for further 
molecular assays. In case of ambiguous species identifica-
tion with the Vitek-2 system, DNA-based identification 
was then performed as described previously (Bosshard 
et al. 2006; Vandercam et al. 2008).
Polymerase chain reaction (PCR) amplification 
and pyrosequencing assay
Primers design
All publicly available nucleotide sequences of blaTEM 
and blaSHV alleles related to ESBL-production pheno-
type (http://www.lahey.org/Studies/) were retrieved from 
the GenBank nucleotide sequence database and aligned 
using the BioNumerics software v7.1. (Applied Maths, 
Sint-Martens-Latem, Belgium). A total of 88 blaTEM 
and 30 blaSHV nucleotide sequences were aligned. Con-
sequently, two simplex qPCRs were designed to amplify 
a 302 bp sequence flanking amino acids 179, 238 and 240 
of blaSHV and a 500 bp sequence flanking positions 104, 
164 and 238 of blaTEM (Table  2). The aforementioned 
positions include indeed the most frequent substitutions 
associated with ESBL-production phenotype (Cohen 
Stuart et  al. 2010). A duplex qPCR was used to amplify 
two blaCTX-M fragments of 224 and 175  bp as previ-
ously described (Naas et al. 2007).
Table 1 Commercial reference strains used as negative and positive controls
TEM104 TEM164 TEM238 SHV179 SHV238 SHV240 Phenotype
ATCC‑35218 (E. coli) Glu104 Arg164 Gly238 – – – Non‑ESBL
ATCC‑700603 (K. pneumoniae) – – – Asp179 Gly238Ala Glu240Lys SHV‑18
DSM‑22313 (E. coli) Glu104Lys Arg164 Gly238Ser – – – TEM‑46
DSM‑22314 (E. coli) Glu104Lys Arg164Ser Gly238 – – – TEM‑50
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Simplex and duplex qPCR amplification
Each qPCR was carried out in 50 μL of a reaction mix-
ture containing 100  pg of extracted DNA as template, 
300  nM of each primer, and 25  μL of Power SYBR® 
Green Reagents 2x (Applied Biosystems, Nieuwekerk, 
The Netherlands). Amplifications were performed either 
on a 7900HT Fast Real-Time PCR System (Applied Bio-
systems, Nieuwekerk, The Netherlands) or a Stratagene 
Mx3005P (Agilent Technologies, Santa Clara, CA, USA). 
The reaction was initiated at 50°C for 2 min and 95°C for 
10 min followed by 45 cycles at 95°C for 15 s and 63°C for 
1 min for the TEM and SHV qPCRs. The duplex CTX-M 
was carried out using the same conditions as above 
except that the optimal annealing temperature was 57°C. 
Finally, a melting curve analysis was performed. Data 
were analyzed using the analytical software SDS 2.4 from 
Applied BioSystem or MxPro qPCR software from Agi-
lent Technologies.
Multiplex pyrosequencing protocol
Pyrosequencing is a bioluminometric assay allowing 
rapid and high throughput sequencing of short DNA 
sequences. This type of assay has already proved it value 
for assessing drug-resistance determining regions in 
various bacteria (Deccache et  al. 2011; Haanperä et  al. 
2005). In order to increase the throughput of the assay, 
two multiplex pyrosequencing assays were concomitantly 
developed using three and two pyrosequencing prim-
ers (Table  2) to generate corresponding sequences for 
blaTEM and blaSHV amplicons, respectively.
The pyrosequencing assay was performed using a Pyro-
Gold SQA sample preparation kit (Qiagen, Hilden, Ger-
many) according to manufacturer’s instructions. Briefly, 
40 µl of biotinylated PCR products were immobilized for 
15  min using 4  µl streptavidin-coated Sepharose beads 
(GE Healthcare-Biosciences AB, Uppsala, Sweden) and 
captured using the Vacuum Prep Tool (Qiagen, Hilden, 
Germany) according to manufacturer’s instructions. 
After a denaturation step (NaOH 0.5 M during 5 s) and 
a wash step for the removal of unlabeled complementary 
DNA of the amplicon, the biotinylated single-stranded 
DNA present on the streptavidin-coated Sepharose beads 
were transferred to a 96-well plate and used as template 
for the pyrosequencing assay with a mixture of sequenc-
ing primers. The TEM mix contained 6, 20 and 60 pmol of 
the TEM-seq104, TEM-seq164 and TEM-seq238 prim-
ers, respectively, whilst the SHV mix contained 60 and 
20  pmol of the SHV-seq179 and SHV-seq238 primers, 
respectively. The pyrosequencing nucleotide dispensa-
tion orders were selected using SENATOR (SElecting the 
Nucleotide dispensATion Order) algorithm (Ambroise 
et  al. 2013). Nucleotide dispensation orders with 15 
(CAGCCTGACATATCA) and 11 (GTGACTGCGTC) 
nucleotides were selected for the triplex TEM and duplex 
SHV assays, respectively. Pyrosequencing was carried out 
using a PSQ 96 MA system (Qiagen, Hilden, Germany).
All multiplex pyrosequencing signals generated for 
TEM and SHV were analyzed using a new web interac-
tive application (available at https://ucl-irec-ctma.shin-
yapps.io/Pyrosequencing-TEM-SHV and in ‘download’ 
section of http://www.uclouvain.be/ctma.html where 
a template data set can be downloaded) written with 
R.3.1.2 software (Ihaka and Gentleman 1996) using the 
“shiny” package. This new application was developed 
using an improved version of three previously published 
algorithms including (1) AdvISER-PYRO for analyz-
ing low and complex signals resulting from samples 
including several mycobacteria (Ambroise et  al. 2013), 
Table 2 List of primers used for ESBL-encoding gene detection and pyrosequencing in Enterobacteriaceae
Degenerate base symbols (IUPAC code): K represents G/T, Y is T/C, S is G/C, R is G/A, M is A/C, H is A/T/C and B is G/T/C.
Target gene Primer name Sequence 5′–3′ qPCR Pyrosequencing assay Reference
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(2) AdvISER-M-PYRO for analyzing overlapping pyro-
signals generated from multiplex reactions conducted 
on mono-allelic genes in bacteria (Ambroise et al. 2014), 
and (3) AdvISER-MH-PYRO for analyzing overlap-
ping pyro-signals generated from multiplex reactions to 
genotype bi-allelic human SNP (Ambroise et  al. 2015). 
While the initial version of AdvISER-M-PYRO analyzed 
multiplex pyrosequencing signals by selecting a single 
and unique sequence for each genomic region, this new 
version enables the analysis of multiplex pyrosequenc-
ing signals generated from samples including two dis-
tinct sequences (i.e., plasmid and chromosomal) for each 
genomic region.
The new web interactive application enables also the 
integration of PCR and pyrosequencing results in order 
to correctly identify the ESBL status of each isolate. In 
that respect, an isolate was considered as ESBL-pro-
ducer organism if either one or more of the ESBL-asso-
ciated substitutions was detected from pyrosequencing 
signals of blaTEM or blaSHV, or if the blaCTX-M 
gene was present (as illustrated on Fig. 1). On the con-
trary, the isolate was considered as non-ESBL-producer 
organism when blaTEM, blaSHV and blaCTX-M genes 
were either not detected or when amplified blaSHV 
or blaTEM genes did not carry any ESBL-associated 
substitution. Pyrosequencing signals displaying low 
signal-to-noise ratio (maximum peak height <10 rela-
tive fluorescence units) and/or a low confidence index 
(R < 0.99) were considered as unsafe and re-tested using 
the same protocol.
Fig. 1 Output illustration of the web interactive application. For a given isolate, integration of PCR and multiplex pyrosequencing results allows the 
determination of the ESBL‑producing status (available at https://ucl‑irec‑ctma.shinyapps.io/Pyrosequencing‑TEM‑SHV/). As demonstrated in this 
example, the algorithm enables to correctly decompose the multiplex pyrosequencing signal generated for the blaSHV gene despite the presence 
of two sequences for the blaSHV238‑240 genomic region (i.e., G238 and E240 on one variant and the G238S‑E240K double substitutions on another 
one).
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Sequencing analysis of amplicons
Sanger sequencing was used to confirm pyrosequencing 
results. Amplifications products of blaTEM and blaSHV 
were purified using MSB® Spin PCRapace purification kit 
(STRATEC Molecular GmbH, Berlin, Germany) accord-
ing to manufacturer’s instructions. After having assessed 
5  µl of each purified PCR product on a 2% (w/v) aga-
rose gel stained with ethidium bromide, corresponding 
amplicons were sequenced in both directions on an auto-
mated ABI 3130 Genetic Analyser apparatus (Applied 
Biosystems, Nieuwekerk, The Netherlands), using the 
BigDye Terminator v3.1 Cycle Sequencing kit from the 
same manufacturer. Nucleotide and deduced amino acid 
sequences were analyzed using the BioNumerics software 
v7.1. (Applied Maths, Sint-Martens-Latem, Belgium) and 
compared to publically available database.
Results
Phenotypic identification of all isolates (n = 330) was as 
follows: Klebsiella pneumonia (n = 147), Escherichia coli 
(n = 119), Klebsiella spp. (n = 30), Enterobacter cloacae 
(n = 16), Proteus mirabilis (n = 10), Serratia marcescens 
(n = 6), and Morganella morgannii (n = 2).
Phenotypic results
ESBL- and non-ESBL-producing organisms were 
assessed by E-test assay in 267/330 (80.9%) and 20/330 
(6.1%) isolates, respectively whereas 43/330 (13%) pre-
sented a MIC value lower than the predefined range, 
hence yielding an ND result. CDT was used to retest 
these 43 isolates displaying a ND E-test, whereupon 36 
isolates were found ESBL-producers and 7 non-ESBL 
producers.
Genotypic results
The newly-developed multiplex pyrosequencing assay 
was used to rapidly assess the ESBL-producing status of 
all isolates following blaTEM, blaSHV and blaCTX-M 
amplification by qPCR. Among all isolates (n = 330), 295 
(89.4%) produced high-quality pyrosequencing signals 
(maximum peak height >10, R  >  0.99) while 35 (10.6%) 
isolates did not meet these quality criteria and where 
therefore re-tested with the same protocol. After this sec-
ond round of analysis, 308 (93.3%) and 22 (6.7%) isolates 
were identified as ESBL- and non-ESBL-producing bacte-
ria, respectively.
The TAT for the analysis was ~5 h (i.e., 40 min for DNA 
purification, 1h50 for the duplex qPCR blaCTX-M, 1h50 
for the concomitant simplex TEM and SHV qPCR, and 
40  min for the multiplex pyrosequencing and data pro-
cessing using the new web interactive application).
It is of note that the Sanger sequence analysis of all 
blaSHV and blaTEM amplification fragments was 
perfectly concordant with the pyrosequencing results 
(data not shown).
Phenotypic: genotypic comparison
Comparison between DNA-based and E-test results is 
detailed in Table 3. When CDT test was combined with 
E-test, a quasi-perfect concordance with results from the 
multiplex DNA-assay was observed (Table 4). Altogether 
after CDT retesting, six results remained discordant: one 
P. mirabilis and four E. coli isolates considered as ‘non-
ESBL producing bacteria’ by CDT despite carrying the 
blaCTX-M gene (Table 4). Conversely, R080 isolate was 
considered as ‘ESBL-producing bacteria’ according to 
E-test, while neither blaSHV, blaTEM, nor blaCTX-M 
genes were detected by qPCR. The ESBL phenotype was 
however confirmed after re-testing this isolate with CDT.
It is of note that another discordant result was observed 
between E-test and DNA-based test on E. cloacae 
MMA55 isolate. This isolate was characterized as ‘non-
ESBL producing bacteria according to the E-test, despite 
the presence of a blaSHV gene with point mutations 
leading to a double E240K and G238S ESBL-associated sub-
stitution. CDT confirmed however the status of ESBL-
produced. The isolate should therefore not be considered 
as a phenotypic-genotypic discordant.
Discussion
A new DNA-based assay has been developed for enabling 
rapid and unambiguous detection of ESBL-producing 
Enterobacteriaceae isolates. The method consists of a 
qPCR amplification of blaTEM, blaSHV and blaCTX-
M and subsequent multiplex pyrosequencing of ESBL 
production-related mutations within blaSHV and 
blaTEM genes. All selected mutations have previously 
been reported (Naas et  al. 2007; Haanperä et  al. 2008; 
Oxacelay et  al. 2009; Jones et  al. 2009; Leinberger et  al. 
2010; Cohen Stuart et  al. 2010; Al-Agamy et  al. 2014). 
Rapid and unambiguous detection methods for ESBL-
production are paramount for appropriate management 
of infectious diseases as it has long been recognized that 
prompt and targeted antibiotic therapy improves the out-
come for patients with infectious diseases (Perez et  al. 
2007). Furthermore, rapid laboratory detection is critical 
for the development of infection control measures aimed 
at reducing the transmission rate of antibiotic-resistant 
microorganisms in hospital wards (Stürenburg and Mack 
2003). Up to now, phenotypic methods have routinely 
been used for detecting antimicrobial resistant isolates, 
and particularly ESBL-producing isolates (Robin et  al. 
2008; Jarlier et al. 1988; Cormican et al. 1996; Carter et al. 
2000). Unfortunately, recent studies have consistently 
pinpointed the many drawbacks affecting these methods. 
These include a long TAT (24–72  h) and somehow low 
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sensitivity and specificity. As an illustration, Garrec and 
co-workers (Garrec et al. 2011) compared various pheno-
typic methods for detecting ESBL production in Entero-
bacteriaceae and found the sensitivity and specificity of 
ESBL-detection using the Vitek-2 to vary between 92 
and 95% in ESBL-producing E. coli isolates while being 
substantially lower (i.e., 50–79%) in ESBL-producing 
K. pneumonia isolates. Lower sensitivity (71%) and 
Table 3 Distribution of the 330 isolates tested, depending on the species, phenotypic test (E-test) and DNA-based test
* Isolates for which genotypic and phenotypic results are discordant. Both discordant isolates and isolates for which E-test yielded a ‘ND’ result (n = 43) were re-tested 
using the combination disk test (CDT).
E‑test DNA‑based test n
CTX‑M TEM SHV Interpretation
E. cloacae, n = 16 ESBL Absent Wild‑type Mutated ESBL 1
Present Absent Absent ESBL 1
Wild‑type Absent ESBL 8
ND Absent Wild‑type Mutated ESBL 1
Present Wild‑type Absent ESBL 4
Non‑ESBL Absent Wild‑type Mutated ESBL* 1*
E. coli, n = 119 ESBL Present Absent Absent ESBL 34
Wild‑type Absent ESBL 50
Mutated ESBL 2
ND Present Wild‑type Absent ESBL 20
Non‑ESBL Absent Absent Absent Non‑ESBL 3
Absent Wild‑type Absent Non‑ESBL 10
K. pneumoniae, n = 147 ESBL Absent Absent Absent Non‑ESBL* 1*
Wild‑type Mutated ESBL 8
Present Absent Wild‑type ESBL 4
Wild‑type Absent ESBL 4
Wild‑type ESBL 73
Mutated ESBL 41
ND Absent Absent Absent Non‑ESBL 2
Wild‑type Mutated ESBL 3
Present Wild‑type Absent ESBL 1
Wild‑type ESBL 5
Mutated ESBL 1
Non‑ESBL Absent Absent Absent Non‑ESBL 2
Wild‑type Non‑ESBL 1
Wild‑type Wild‑type Non‑ESBL 1
Klebsiella spp., n = 30 ESBL Present Absent Wild‑type ESBL 1
Wild‑type Absent ESBL 13
Wild‑type ESBL 5
Mutated ESBL 10
ND Present Wild‑type Absent ESBL 1
P. mirabilis, n = 10 ESBL Present Wild‑type Absent ESBL 1
Wild‑type ESBL 1
Mutated ESBL 2
ND Absent Wild‑type Mutated ESBL 3
Present Absent Absent ESBL 1
Non‑ESBL Absent Absent Absent Non‑ESBL 2
S. marcescens, n = 6 ESBL Present Wild‑type Absent ESBL 5
ND Present Wild‑type Absent ESBL 1
M. morganii, n = 2 ESBL Present Absent Absent ESBL 1
Wild‑type Absent ESBL 1
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specificity (73%) were also reported when using the E-test 
for detecting ESBL-production in Enterobacteriaceae iso-
lates (Garrec et al. 2011). Moreover, E-test method often 
yields ND results with some isolates (Leverstein-van Hall 
et al. 2002). Finally, interpretation of results according to 
various breakpoints also impacts the interpretation of 
ESBL-production.
Multiplex DNA-based assays targeting specific muta-
tions related to ESBL-production phenotype are expected 
to circumvent at least part of these difficulties. Whereas 
molecular methods are usually considered as exquisitely 
sensitive and specific for rapidly and directly assess-
ing the ESBL-production status in bacterial isolates, it 
should be pointed out that few of them have, up to now, 
convincingly demonstrated their capacity to be usefully 
translated into the routine practice of clinical micro-
biology. Consequently, the main goal was to develop a 
multiplex DNA-based assay which could easily be imple-
mented in a clinical setting, while swiftly delivering a reli-
able ESBL-status for Enterobacteriaceae isolates. In that 
respect, qPCR amplification, multiplex pyrosequencing, 
and signal analysis were combined in order to develop 
a quick and reliable assay. The signal analysis algorithm 
was implemented in a new web interactive application 
that allowed to correctly decomposing triplex and duplex 
pyrosequencing signals. While a concomitant pres-
ence of chromosomal and plasmid β-lactamase variants 
within the same isolate does not preclude determining its 
ESBL phenotype, it may affect the pyrosequencing result 
of ESBL genes located on the plasmid (Haanperä et  al. 
2008; Jones et al. 2009). Consequently, the new algorithm 
was designed to correctly deciphering multiplex pyrose-
quencing signals generated from samples including two 
distinct sequences (i.e., plasmid and chromosomal) for 
each genomic region, as illustrated in Fig. 1.
Compared to phenotypic testing (E-test or CDT), the 
TAT for the combined multiplex assay was short (~5 h). 
In addition, result interpretation is rendered easier and 
more reproducible by the use of the new web interactive 
application. To further shorten the TAT, it should also be 
noted that DNA extraction could be sidestepped while 
carrying out multiplex amplification directly in triplicate 
with each isolated bacterial colony, after boiling. Moreo-
ver, this multiplex assay appears suitable for simultaneous 
and high-throughput determination of ESBL-production 
status on up to 30 isolates per run. Conversely, only 6 
isolates could be processed per run if the same test was 
to be carried out in conventional simplex pyrosequenc-
ing format (i.e., one well per pyrosequencing reaction). 
While the difference between low-cost phenotypic test 
and DNA-based protocol was important when consid-
ering conventional simplex pyrosequencing, the combi-
nation of the five uniplex pyrosequencing reactions into 
two multiplex reactions allowed reducing this gap.
In this study, 43 isolates did not yield MIC values compat-
ible with ESBL-production when using E-test strips. This 
prompted us to use CDT as complementary test in order 
to assess and confirm the ESBL-status. As indicated above, 
Table 4 Distribution of the 45 isolates re-tested using the CDT (43 with a ND and 2 with discrepant results between E-test 
and DNA-based assay)
* Isolates for which genotypic and phenotypic results are discordant. Both discordant isolates and isolates for which E-test yielded a ‘ND’ result (n = 43) were re-tested 
using the combination disk test (CDT).
Phenotypic test DNA‑based test n
E‑test CD CTX‑M TEM SHV Interpretation
E. cloacae, n = 6 ND ESBL Absent Wild‑type Mutated ESBL 1
ESBL Present Wild‑type Absent ESBL 4
Non‑ESBL (MMA55)* ESBL* Absent Wild‑type Mutated ESBL* 1*
E. coli, n = 20 ND ESBL Present Wild‑type Absent ESBL 16
Non‑ESBL* Present Wild‑type Absent ESBL* 4*
K. pneumoniae, n = 13 ND Non‑ESBL Absent Absent Absent Non‑ESBL 2
ESBL Absent Wild‑type Mutated ESBL 3
Present Wild‑type Absent ESBL 1
Wild‑type ESBL 5
Mutated ESBL 1
ESBL (R080)* ESBL* Absent Absent Absent Non‑ESBL* 1*
Klebsiella spp., n = 1 ND ESBL Present Wild‑type Absent ESBL 1
P. mirabilis, n = 4 ND ESBL Absent Wild‑type Mutated ESBL 3
Non‑ESBL* Present Absent Absent ESBL* 1*
S. marcescens, n = 1 ND ESBL Present Wild‑type Absent ESBL 1
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this process results in extending the TAT which, in turn, 
could be detrimental for the patient’s health. With the lat-
ter 43 isolates, the multiplex DNA-based assay gave rapid 
and unambiguous ESBL characterization. Comparing the 
results of genotypic and phenotypic tests showed however a 
discrepant result with five isolates (i.e., four E. coli and one 
P. mirabilis). In all discrepant cases, E-test and CDT gave 
an indeterminate result and ‘non-ESBL’ phenotype, respec-
tively. Considering the presence the blaCTX-M gene in the 
five isolates, it seems clear that CDT produced false-negative 
results. According to guidelines published by the European 
Committee on Antimicrobial Susceptibility Testing (Giske 
et  al. 2013), this type of results may occur when bacteria 
expressed either a high-level AmpC β-lactamase (Drieux 
et al. 2008; Jacoby 2009; Munier et al. 2010), either carbap-
enemases (such as KPCs or MBLs Tsakris et al. 2009; March 
et al. 2010) and/or severe permeability defects. The presence 
of such mechanisms could mask the presence of ESBLs.
The case of MMA55 (E. cloacae) isolate is also interest-
ing as it pinpoints the added value of the current multi-
plex DNA-based assay compared to phenotypic tests. 
This isolate was indeed initially characterized as ‘non-
ESBL’ by the gradient test even though multiplex qPCR 
and pyrosequencing revealed the presence of a SHV vari-
ant harboring ESBL-associated substitutions (E240K and 
G238S). Subsequent CDT results were however in line 
with the ESBL-genotypic result.
Another interesting case was R080 (K. pneumoniae) 
isolate. Though clearly displaying an ESBL-phenotype, 
this isolate was lacking the three antibiotic resistance 
determinant genes as targeted by our qPCR assay. This 
phenotype could result from the presence of less fre-
quent ESBL genes, such as PER, VEB, SME or BEL. Iso-
lates displaying a similar pattern have indeed previously 
been described by others (Nijhuis et al. 2012). Investigat-
ing these rare genes fell however beyond the immediate 
scope of this work but investigations will be pursued to 
understand this apparent discrepancy and to test this 
hypothesis. By the way, the flexibility of this multiplex 
pyrosequencing assay makes it perfectly suitable for add-
ing new ESBL family or genetic variant pending their dis-
covery and demonstration of interest.
Like with most DNA-based tests, it must be empha-
sized that the current assay detects a spectrum of com-
mon and highly prevalent ESBL-associated mutations 
without a precise identification thereof. If this informa-
tion is required, full-length gene sequencing would need 
to be carried out for characterization of the genetic vari-
ant for point mutations.
One major potential drawback which so far precludes 
implementing DNA-based methods in routine microbi-
ology is the risk of carry-over contamination. Whereas 
this risk needs always to be thoroughly assessed, it can 
be lowered to an acceptable threshold by incorporating 
UNG-ampErase in PCR mix (Longo et  al. 1990) as well 
as by performing qPCR preparations and pyrosequencing 
reactions in separate rooms.
In conclusion, the assay developed in this study can be 
considered as a bona fide surrogate for ESBL-detection in 
clinical settings. Moreover, the current multiplex pyrose-
quencing assay is an innovative high-throughput; rapid 
and reliable assay drastically limiting the use of DNA while 
reducing analytical costs and waste material disposal.
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